QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, July 18, 2007, 27(29):7648-7653; doi:10.1523/JNEUROSCI.0395-07.2007

This Article Abstract Full Text (PDF) Supplemental Data Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Knobloch, M. Articles by Mansuy, I. M. Search for Related Content PubMed PubMed Citation Articles by Knobloch, M. Articles by Mansuy, I. M.

 Previous Article  |  Next Article 

Brief Communications
Aß Oligomer-Mediated Long-Term Potentiation Impairment Involves Protein Phosphatase 1-Dependent Mechanisms

Marlen Knobloch,^1 * Mélissa Farinelli,^2 * Uwe Konietzko,¹ Roger M. Nitsch,¹  and Isabelle M. Mansuy² 

¹Division of Psychiatry Research, University of Zurich, 8008 Zurich, Switzerland, and ²Brain Research Institute, University of Zurich and Department of Biology, Swiss Federal Institute of Technology, 8057 Zurich, Switzerland

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Amyloid ß (Aß) oligomers are derived from proteolytic cleavage of amyloid precursor protein (APP) and can impair memory and hippocampal long-term potentiation (LTP) in vivo and in vitro. They are recognized as the primary neurotoxic agents in Alzheimer's disease. The mechanisms underlying such toxicity on synaptic functions are complex and not fully understood. Here, we provide the first evidence that these mechanisms involve protein phosphatase 1 (PP1). Using a novel transgenic mouse model expressing human APP with the Swedish and Arctic mutations that render Aß more prone to form oligomers (arcAß mice), we show that the LTP impairment induced by Aß oligomers can be fully reversed by PP1 inhibition in vitro. We further demonstrate that the genetic inhibition of endogenous PP1 in vivo confers resistance to Aß oligomer-mediated toxicity and preserves LTP. Overall, these results reveal that PP1 is a key player in the mechanisms of AD pathology.

Key words: impairment; PP1; oligomers; Aß-peptide; Alzheimer's disease; LTP

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Recent progress in the field of Alzheimer's disease (AD) has provided evidence that amyloid ß (Aß) oligomers rather than ß-amyloid plaques are the major toxic agents in the pathology of the disease (Selkoe, 2002). Aß oligomers have been demonstrated to disrupt synaptic plasticity and impair memory (Lambert et al., 1998; Walsh et al., 2002; Oddo et al., 2003; Lesne et al., 2006) and are known to accumulate in the brain of AD patients (Takahashi et al., 2002). Therapeutic strategies developed to interfere with Aß deposition and clearance have shown initial benefit in AD patients and rodent models (Hock et al., 2003; Klyubin et al., 2005; Schenk et al., 2005). Neutralization of Aß toxicity, for instance, was found to reverse memory deficits in a mouse model of AD without altering ß-amyloid plaque load (Dodart et al., 2002).

Many studies have attempted to determine the mechanisms by which Aß assemblies disrupt synaptic plasticity and mediate their detrimental effect, but the actual pathways that couple Aß toxicity to synaptic functions remain only partially understood. A recently identified mechanism implicates specific interactions between Aß and neurotransmitter receptors such as the NMDA (Snyder et al., 2005; Kelly and Ferreira, 2006) and -7 nicotinic acetylcholine receptors (Oddo and LaFerla, 2006). This mechanism was shown to recruit the Ca²⁺-dependent protein phosphatase calcineurin (PP2B) (Chen et al., 2002; Snyder et al., 2005; Kelly and Ferreira, 2006), a finding in line with the hypothesis that Ca²⁺ signaling is disrupted by Aß neurotoxicity (Demuro et al., 2005).

To investigate whether other major signaling pathways downstream of the NMDA receptor are implicated in the mechanisms of Aß toxicity in vivo, we generated a transgenic mouse model expressing a human amyloid precursor protein (APP) with the Swedish and Arctic mutations (arcAß mice) that produces a form of Aß more prone to yield Aß oligomers (Knobloch et al., 2007). In these mice, expression of the mutant APP induces punctate intraneuronal Aß deposition in several brain areas and severe behavioral deficits before the onset of extracellular ß-amyloid plaque deposition. Using this model, we show here that the overproduction of Arctic Aß is associated with an age-dependent impairment in hippocampal long-term potentiation (LTP) and synaptic plasticity in vitro that involves protein phosphatase 1 (PP1)-dependent mechanisms. Furthermore, we demonstrate that both the pharmacologic and genetic inhibition of PP1 in vitro and in vivo reverse the defect in synaptic plasticity induced by Aß oligomers. These results strongly support a major role for PP1 in the mechanisms of Aß oligomer-mediated toxicity and demonstrate its reversibility in adult animals.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Animals. ArcAß mice, APPSwe/PS1 mice, and I-1* mutant mice were obtained by breeding as described previously (Holcomb et al., 1998; Genoux et al., 2002; Michalon et al., 2005; Knobloch et al., 2007). ArcAß mice express human APP 695 carrying both the Swedish (K670N; M671L) and the Arctic (E693G) mutations in a single construct under the control of the prion protein promoter. APPSwe/PS1 mice carry a human APP with the Swedish mutation and a mutant presenilin 1 (M146L). I-1* mutant mice carry a transgene expressing an rtTA2 factor under the control of the calcium/calmodulin-dependent kinase II (CaMKII) promoter and a transgene carrying a tetO promoter fused to I1* cDNA. Mice were kept under standard housing conditions on a reversed 12 h light/dark cycle with food and water ad libitum. Seven to nine days before the experiments, I-1* mutant mice and control littermates (carrying only the tetO-I-1* transgene) were fed doxycycline (West-Ward Pharmaceuticals, Eatontown, NJ) at 6 mg/g of food. All animal experiments were performed in accordance with guidelines of the Swiss veterinary cantonal office (licenses Nr 150/06 and 123/04).

Electrophysiological recordings. Mice were anesthetized with isoflurane and then decapitated. Heads were immediately immersed in ice-cold freshly prepared artificial CSF (aCSF) for at least 2 min before brain extraction. Acute slices (400 µm thick) were prepared with a vibratome (VT 1000S; Leica Microsystems, Bannockburn, IL) in ice-cold gassed aCSF. Sections were incubated in aCSF at 34°C for 20 min and then kept at room temperature for at least 1 h before recording. Recording was performed in an interface chamber continuously flowed with aCSF at 1.1 ml/min. A monopolar electrode was placed in the Schaffer collaterals, and stimulation was applied at 0.033 Hz with stimulus intensity ranging from 20 to 80 µA, yielding evoked field EPSPs (fEPSPs) of 0.2–0.5 V. fEPSPs were recorded in the stratum radiatum using a borosilicate micropipette filled with aCSF. The signal was amplified with an Axopatch 200B amplifier (Molecular Devices, Union City, CA), digitized by a Digidata 1200 interface (Molecular Devices) and sampled at 10 kHz with Clampex 8.2 (Molecular Devices). aCSF was composed of the following (in mM): 119 NaCl, 11 D-glucose, 1.3 MgCl₂.6H₂O, 1.3 NaH₂PO₄, 2.5 KCl, 2.5 CaCl₂, 26 NaHCO₃, gassed with O₂/CO₂ (95/5%) at least 20 min before use and throughout the experiment. Baseline was recorded for a minimum of 20 min or until stable. Plasticity was then induced by stimulation with either 1 Hz for 15 min (900 pulses), 2 Hz for 10 min (1200 pulses), 5 Hz for 3 min (900 pulses), 10 Hz for 1.5 min (900 pulses), or 100 Hz for three trains of 1 s tetanus separated by 20 s. Data were analyzed by measuring the slope of individual fEPSPs at 1–1.5 ms after the stimulus pulse by linear fitting using Clampfit (Molecular Devices). The frequency-dependent plasticity curve (BCM curve) was built by determining mean fEPSP slopes over 10 min starting 35 min after stimulation (according to Jouvenceau et al., 2006).

Reverse transcription and quantitative real-time PCR. Total RNA was isolated from frozen hippocampi of 6-month-old arcAß mice and wild-type littermates (n = 5 for each) with TRIzol (Invitrogen, Carlsbad, CA) and cleaned up with RNeasy Mini kit (Qiagen, Valencia, CA). First-strand cDNA was synthesized using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) according to the manufacturer's protocol. Real-time PCR was performed on TaqMan (ABI PRISM 7700 SDS) using SYBR Green (Applied Biosystems, Foster City, CA). Primer sequences were as follows: NMDA receptor subunit 2B (NR2B) forward (for.), AAGACAAGGGCCGATTCATG; reverse (rev.), GCAAAGGAGCTCTCACCAGC; CaMKII for., AGTCAGAGGAGACCCGCGT; rev., TGTGGAAGTGGACGATCTGC; glutamate receptor 1 (GluR1) for., CAATGTGGCAGGCGTGTTC; rev., TCGATTAAGGCAACCAGCATG; Syn.physin for., AAGGTGCTGCAGTGGGTCTTT; rev., CGAAGCTCTCCGGTGTAGCT; Zif268 for., CGAGAAGCCTTTTGCCTGTG; rev., TGGTATGCCTCTTGCGTTCA; Arc for., TGGAGGGAGGTCTTCTACCGT; rev., TATTTGCCGCCCATGGACT; ß-actin for., TACTCTGTGTGGATCGGTGGC; rev., TGCTGATCCACATCTGCTGG; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for., GGCATCTTGGGCTACACTGAG; rev., CGAAGGTGGAAGAGTGGGAG.

Data analysis was performed according to the Ct method, normalized to ß-actin and GAPDH. Statistical analysis was performed on the Ct values using Student's t test.

Passive immunization. Three-month-old arcAß mice were immunized with a single intraperitoneal injection (10 mg/kg) of either purified 6E10 (Signet, Dedham, MA) or negative control antibody for mouse IgG₁ (Lab Vision, Fremont, CA) 48 h before slice preparation.

Tautomycin application. Slices from 3-month-old arcAß mice, wild-type littermates, and APPSwe/PS1 mice were bathed in normal aCSF or aCSF containing 1 nM tautomycin (Sigma, St. Louis, MO) for at least 1 h before recording.

PP1 activity assay. Activity of recombinant PP1 (New England Biolabs, Beverly, MA) and calcineurin (Biomol, Plymouth Meeting, PA) was measured with and without 1 nM tautomycin using a modified Biomol Green Assay kit (Biomol).

Western blot analysis of phospho-CaMKII levels. Mice were perfused transcardially with ice-cold PBS, and hippocampi were dissected and immediately frozen in dry ice. Crude synaptic membrane fractions were prepared according to Genoux et al. (2002). Equal amount of proteins was loaded and separated by SDS-PAGE, transferred to a nitrocellulose membrane, and blocked in TBS containing 1% BSA and 0.1% Triton X-100. Primary antibodies [anti-phospho-CaMKII antibody, 1:1000 (Millipore, Billerica, MA); anti-total CaMKII antibody, 1:10,000 (Millipore); and anti-ß-actin antibody, 1:5000 (Abcam, Cambridge, MA)] were incubated overnight at 4°C, and the corresponding secondary antibodies were incubated for 1.5 h at room temperature. Commercial ECL (GE Healthcare, Piscataway, NJ) was used for the detection of chemiluminescence. Densitometric analysis was performed using the free downloadable ImageJ software (http://rsb.info.nih.gov/ij/).

Aß oligomer preparation and application. Aß oligomers were prepared according to Klein (2002). Synthetic Aß_1–42 (Bachem, King of Prussia, PA) was dissolved in Hexafluor2-propanol (HFIP), aliquoted, and kept at –80°C after evaporation of HFIP. Aß oligomers were prepared freshly by dissolving the above peptide film with DMSO and diluting it into cold F12 medium without phenol red to yield a 100 µM stock. This preparation was incubated at 4°C for 24 h and centrifuged at 14,000 x g for 10 min at 4°C, and the supernatant was further used for electrophysiological experiments according to Wang et al. (2002). Slices were bathed for at least 1 h in aCSF containing either Aß oligomers (1:200 diluted) or, as a control, phenol red-free F12 medium only (1:200 diluted). To prevent a washout of Aß oligomers during recording, the aCSF used for perfusion contained a 1:400 dilution of Aß oligomers/phenol red-free F12, respectively. Each Aß oligomer preparation was used for one I-1* mutant mouse and a corresponding control in parallel, measured in a blinded manner.

Electron microscopy. The Aß oligomer preparation was controlled by electron microscopy. Five microliters of the above supernatant were adsorbed onto glow-discharged, 300-mesh carbon-coated Formvar grids for 2–3 min, negatively stained with 2% phosphorwolfram acid for 45 s, and viewed with a Philips CM12 scanning transmission electron microscope.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Severe impairment in synaptic plasticity in arcAß mice
To evaluate the effect of arcAß on synaptic plasticity, we first measured hippocampal LTP in area CA1 in vitro by recording fEPSPs in acute slices from adult arcAß mice and wild-type littermates after 100 Hz stimulation. LTP was severely impaired in slices from 3.5- and 7.5-month-old arcAß mice (Fig. 1A,B) (p < 0.001; repeated-measurement ANOVA), with fEPSPs returning to baseline within 10 min after LTP induction. The LTP deficit was not caused by impaired synaptic transmission, because basal transmission was normal in the transgenic slices (Fig. 1A,B, inset). It did not result from a developmental defect caused by transgene expression either, because both LTP (Fig. 1C) and basal synaptic transmission (Fig. 1C, inset) were normal in slices from 1-month-old mice, consistent with the fact that Aß accumulation is not detectable at this age despite high expression of mutant APP (Knobloch et al., 2007). We confirmed that the LTP deficit was caused by Aß oligomers by showing that it could be reversed with a single dose of an antibody directed against the Aß sequence (6E10) administered to the animals 48 h before LTP induction (supplemental Fig. 1, available at www.jneurosci.org as supplemental material). The antibody treatment restored LTP in transgenic slices to 85% level of potentiation compared with slices from wild-type littermates. A control antibody of the identical IgG class against a nonrelated antigen failed to rescue LTP (supplemental Fig. 1, available at www.jneurosci.org as supplemental material). In addition to a deficit in plasticity at high induction frequency (100 Hz for LTP), stimulation frequencies of 5 and 10 Hz also showed reduced fEPSP potentiation in slices from arcAß mice compared with wild-type slices. Plasticity at 1 or 2 Hz stimulation frequency was not changed (Fig. 2D). These results reveal a deficit in plasticity across a wide range of stimulation frequencies with a shift of responses toward synaptic depression.

View larger version (34K): [in this window] [in a new window]   Figure 1. CA1 hippocampal LTP is impaired in arcAß mice. A, B, CA1 hippocampal LTP is severely impaired in slices from 3.5- and 7.5-month-old arcAß mice (n = 5 tg, 5 wt mice) but basal transmission is normal (right inset). C, LTP and basal transmission (right inset) are normal in slices from 1-month-old arcAß mice (n = 5 tg, 5 wt mice). Left insets, Individual fEPSP traces for tg and wt mice before (black) and after (red) LTP induction. Calibration: A, B, 0.4 mV, 5 ms; C, 0.6 mV, 5 ms. D, Real-time RT-PCR: normal mRNA expression of synaptophysin, NMDA and AMPA receptors, and CaMKII, but reduced arg3.1 (67%; range, 58–78%; n = 5 tg and 5 wt mice) and zif268 (52%; range, 45–61%) expression in the hippocampus of 6-month-old arcAß mice. Error bars represent SEM. *p < 0.05. norm., Normalized; Synapto., synaptophysin; Tg, transgenic.

 

View larger version (33K): [in this window] [in a new window]   Figure 2. In vitro inhibition of PP1 reverses Aß oligomer-mediated LTP impairment. A, B, PP1 is inhibited by bath application of 1 nM tautomycin (tauto) in slices from 3-month-old arcAß mice and wild-type littermates. Tautomycin fully reverses the LTP deficit in slices from tg mice (n = 5) but has no effect in wt (n = 5 mice). It also does not change basal transmission (right insets). Left insets, Individual fEPSP traces for tg and wt mice before (black) and after (red) LTP induction. Calibration: 0.3 mV, 5 ms. C, Phosphatase activity assays showing that 1 nM tautomycin specifically inhibits the activity of recombinant PP1 but not of recombinant calcineurin. D, Frequency–response curve showing mean fEPSP slopes over 10 min starting 35 min after stimulation with 1, 2, 5, 10, and 100 Hz in slices from tg and wt mice treated or not with tautomycin (n = 3–5 slices per condition and frequency). E, PP1 inhibition with 1 nM tautomycin also reverses the LTP deficit seen in 3-month-old APPSwe/PS1 mice, another mouse model of AD (n = 5 tg). Error bars represent SEM. CN, Calcineurin; Tg, transgenic; w/o, without.

 
To examine whether candidate genes involved in synaptic signaling may underlie the impairment in plasticity induced by Aß oligomers, we measured the level of expression of several candidate genes by real-time reverse transcription (RT)-PCR. Hippocampal expression of synaptophysin, a synaptic vesicle protein involved in neurotransmitter release, the NR2B and GluR1 subunits of the NMDA and AMPA receptors critical for glutamatergic neurotransmission, or CaMKII, a major protein kinase necessary for the induction of LTP (Lisman et al., 2002), was not altered in arcAß mice (Fig. 1D). However, because intracellular Ca²⁺ signaling is altered by Aß oligomers, it is likely that Ca²⁺-dependent posttranslational processes such as protein phosphorylation are perturbed. Therefore, we examined whether phosphorylation of CaMKII is changed in arcAß mice. Western blot analyses revealed a decrease in the level of phosphorylated CaMKII in synaptic membranes from arcAß mice (supplemental Fig. 2, available at www.jneurosci.org as supplemental material), suggesting a perturbation in protein kinase/phosphatase pathways. Furthermore, the expression of transcription factors rapidly activated after neuronal activity and required for LTP, arg3.1/arc and zif268 (Worley et al., 1991; Link et al., 1995; Guzowski et al., 2000), was significantly reduced in arcAß mice (Fig. 1D) [p < 0.05; t test; mean and range percentage change versus wild type (wt): arg3.1, 67% (58–78%); zif268, 52% (45–61%)]. These results therefore indicate that Aß oligomers alter protein phosphorylation and the activation of immediate early genes (IEGs).

In vitro inhibition of PP1 reverses Aß oligomer-mediated plasticity impairment
Because PP1 is a major protein phosphatase in neurons that negatively regulates intracellular signaling downstream from the NMDA receptor (including CaMKII) and modulates hippocampal LTP (Jouvenceau et al., 2006; Mansuy and Shenolikar, 2006), we examined whether it might be involved in the deficit in plasticity induced by Aß oligomers. PP1 was inhibited pharmacologically in acute hippocampal slices from arcAß mice and wild-type littermates using the selective inhibitor tautomycin (1 nM), and the effect on plasticity was examined across several stimulation frequencies. Remarkably, PP1 inhibition was found to fully reverse the deficit in plasticity observed at 5, 10, or 100 Hz in arcAß slices (Fig. 2A,D) (p < 0.05; repeated-measurement ANOVA) but had no effect on plasticity in wild-type slices (Fig. 2B) (p = 0.3; repeated-measurement ANOVA). This rescuing effect resulted specifically from PP1 inhibition and did not involve the protein phosphatase calcineurin because only PP1 activity was significantly inhibited by 1 nM tautomycin (Fig. 2C), confirming that PP1-dependent mechanisms are involved in the plasticity deficit.

To confirm the rescuing effect of PP1 inhibition observed in arcAß mice, we examined whether it could be reproduced in another transgenic mouse model of AD. We tested the well established APPSwe/PS1 model that expresses human APP carrying the Swedish mutation and a mutated Presenilin1 and exhibits an early AD pathology associated with marked behavioral deficits (Holcomb et al., 1998). Similarly to arcAß mice, CA1 hippocampal LTP was severely impaired in 3-month-old APPSwe/PS1 animals and was significantly rescued by PP1 inhibition (1 nM tautomycin) (Fig. 2E) (p < 0.05; repeated-measurement ANOVA). The rescue was however less pronounced than in arcAß mice, possibly because of higher production of the more toxic Aß_1–42 as a result of the presenilin mutation in APPSwe/PS1. Together, these results strongly suggest that PP1 is a critical factor in the course of Aß-mediated toxicity.

Inhibition of endogenous PP1 in vivo confers resistance to Aß oligomer-mediated toxicity
To assess whether the detrimental effect of PP1 is also reversible in vivo, we examined whether inhibition of endogenous PP1 before exposure to Aß oligomers confers resistance to Aß oligomer-mediated toxicity. We took advantage of a transgenic mouse model in which PP1 is selectively inhibited (by 40–60%) in forebrain neurons by expression of a constitutively active form of the PP1 inhibitor-1 (I-1*) (Genoux et al., 2002; Michalon et al., 2005). Acute slices from adult I-1* transgenic mice were exposed to Aß oligomers produced from synthetic Aß_1–42. This preparation of Aß oligomers contained globular Aß assemblies of 7–12 nm diameter (Fig. 3A), as previously described (Klein, 2002). To verify that our preparation of Aß oligomers had the reported inhibitory effect on LTP (Wang et al., 2002), we bathed slices from wild-type mice in aCSF containing Aß oligomers (0.5 µM of the initial peptide) or normal aCSF. As expected, Aß oligomers strongly impaired the induction of LTP in slices from wild-type mice, and fEPSPs returned to baseline within 10 min after tetanic stimulation (Fig. 3B). Likewise, Aß oligomers impaired LTP in slices from I-1* control littermates (Fig. 3C) (p < 0.05; repeated-measurement ANOVA). However, in slices from I-1* transgenic mice, Aß oligomers did not prevent the induction of LTP, which was robust and stable (Fig. 3D) (p = 0.6; repeated-measurement ANOVA comparing LTP with and without Aß oligomers). These results therefore indicate that PP1 inhibition in vivo confers protection against Aß oligomer-mediated toxicity.

View larger version (44K): [in this window] [in a new window]   Figure 3. Endogenous PP1 inhibition in vivo confers resistance to Aß oligomer-mediated toxicity. A, Electron microscopy of Aß oligomer preparation produced from synthetic Aß1–42 (according to Klein, 2002) showing globular Aß assemblies of 7–12 nm after 24 h incubation at 4°C. Scale bar, 200 nm. B, Confirmation of Aß oligomer-mediated toxicity in wt mice. Aß oligomers were bath applied to wt slices for at least 1 h. Aß oligomers impair LTP (n = 3–4; 3 slices with Aß oligomers and 4 control slices). Right inset, Basal transmission was not affected. Left insets, Individual fEPSP traces with and without Aß oligomer application before (black) and after (red) LTP induction. Calibration: 0.6 mV, 5 ms. C, D, Aß oligomers are bath applied for at least 1 h to slices from I-1* transgenic mice and control littermates. Aß oligomers impair LTP in I-1* control mice (n = 5) but not in I-1* transgenic mice (n = 5). Right inset, Basal transmission is not affected. Left insets, Individual fEPSP traces with and without application of Aß oligomers before (black) and after (red) LTP induction. Calibration: 0.6 mV, 5 ms. Error bars represent SEM. oligo., Oligomer.

 

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
This study demonstrates that the inhibitory effects of Aß oligomers on hippocampal LTP in the adult brain are reversible and that normal LTP can be restored by PP1 inhibition in vitro in independent mouse models of AD (arcAß mice and APPSwe/PS1 mice). It also reveals that in addition to LTP induced by 100 Hz stimulation, Aß oligomers perturb synaptic plasticity in the hippocampus at intermediate frequencies (5 and 10 Hz) and induce a general shift in synaptic responses toward depression that, similar to LTP, can be fully reversed by PP1 inhibition. Endogenous PP1 inhibition in vivo is further shown to prevent the impairment of LTP induced by Aß oligomers, providing strong evidence that PP1 is a critical player in the mechanisms of Aß oligomer-mediated toxicity.

Although the mechanisms of Aß action are not fully understood, our results provide evidence that, in addition to involving PP1-dependent processes, they also implicate CaMKII and IEGs. CaMKII, arg3.1, and zif268 are traditionally known as key molecules in the mechanisms of LTP and memory formation (Jones et al., 2001; Lisman et al., 2002; Tzingounis and Nicoll, 2006) and have also been implicated in ß-amyloid pathology (Dickey et al., 2003; Lin et al., 2004). The novel correlation that our results reveal between these molecules and PP1 suggests that they may be downstream targets of PP1-dependent pathways perturbed by Aß oligomers. This may involve direct dephosphorylation of CaMKII by PP1, because CaMKII is a known target of PP1 (Strack et al., 1997) and could account for the alteration in plasticity in our model, which is severe, despite normal expression of NMDA and AMPA receptors and synaptophysin. Interestingly, PP1 inhibition in vivo has been shown to increase CaMKII phosphorylation, shift hippocampal plasticity toward potentiation (Jouvenceau et al., 2006), and reverse cognitive deficits in aged mice (Genoux et al., 2002). The present results significantly extend these previous findings by demonstrating the relevance of these PP1-dependent pathways in the mechanisms of AD. The present findings further underscore the implication of dysfunctional protein phosphorylation in AD pathology and highlight the importance of protein phosphatases in this pathology. The importance of their contribution is clearly reflected by the fact that the deficits in plasticity associated with the pathology are fully reversible, just like protein phosphorylation is. Because PP1 is a major protein phosphatase in neuronal cells, multiple targets and pathways are likely to be modified, such as phosphorylation or trafficking of glutamate receptors, as recently shown in primary neurons and organotypic brain slices from AD mouse models (Snyder et al., 2005; Hsieh et al., 2006).

Finally, the severe LTP impairment observed in young arcAß mice (3 months) when no ß-amyloid plaques are detectable supports the hypothesis that oligomeric Aß species are major contributors to synaptic failure in AD (for review, see Rowan et al., 2003). The rescue of LTP achieved with a single dose of an antibody directed against the Aß sequence confirms this hypothesis and suggests that such antibodies may be useful in immunotherapeutic strategies against AD (Rowan et al., 2005). In our model, the reduced arg3.1 and zif268 expression occurs before any detectable extracellular ß-amyloid deposition, supporting the evidence that disruption of synaptic plasticity is an early event in the course of the disease. Overall, these results point to PP1 as a promising target for the development of potential therapeutic approaches against Aß-mediated toxicity in AD.

	Footnotes

 
Received Jan. 29, 2007; revised May 10, 2007; accepted May 10, 2007.

*M.K. and M.F. contributed equally to this work.

R.M.N. and I.M.M. contributed equally to this work.

This work was supported in part by Swiss National Science Foundation Grant 3200B0-112616, the National Center for Competence in Research (NCCR) "Neuronal Plasticity and Repair," and European Union contract LSHM-CT-2003-503330 (APOPIS). The laboratory of I.M.M. was supported by the University Zurich, the Swiss Federal Institute of Technology Zurich, the Swiss National Science Foundation, NCCR "Neural Plasticity and Repair," Human Frontier Science Program, the Slack-Gyr Foundation, and the Bitterlin Foundation. We thank Dr. Sandor Vizi for preparing the I-1* transgenic mice and Karen Duff and Karen Ashe for providing the original PS1 mouse line and the Swedish mouse line. We acknowledge the laboratory of electron microscopy (University of Zurich) for the support with electron microscopy.

Correspondence should be addressed to either of the following: Isabelle M. Mansuy, Brain Research Institute, University of Zurich/Eidgenössische Technische Hochschule Zürich, Winterthurerstrasse 190, 8057 Zurich, Switzerland, Email: mansuy{at}hifo.unizh.ch; or Roger M. Nitsch, Division of Psychiatry Research, University of Zurich, August Forel-Strasse 1, 8008 Zurich, Switzerland, Email: nitsch{at}bli.unizh.ch

Copyright © 2007 Society for Neuroscience 0270-6474/07/277648-06$15.00/0

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

Chen QS, Wei WZ, Shimahara T, Xie CW (2002) Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem 77:354–371.[CrossRef][Web of Science][Medline]

Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280:17294–17300.[Abstract/Free Full Text]

Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan D (2003) Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 23:5219–5226.[Abstract/Free Full Text]

Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5:452–457.[Web of Science][Medline]

Genoux D, Haditsch U, Knobloch M, Michalon A, Storm D, Mansuy IM (2002) Protein phosphatase 1 is a molecular constraint on learning and memory. Nature 418:970–975.[CrossRef][Medline]

Guzowski JF, Lyford GL, Stevenson GD, Houston FP, McGaugh JL, Worley PF, Barnes CA (2000) Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J Neurosci 20:3993–4001.[Abstract/Free Full Text]

Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547–554.[CrossRef][Web of Science][Medline]

Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97–100.[CrossRef][Web of Science][Medline]

Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52:831–843.[CrossRef][Web of Science][Medline]

Jones MW, Errington ML, French PJ, Fine A, Bliss TV, Garel S, Charnay P, Bozon B, Laroche S, Davis S (2001) A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci 4:289–296.[CrossRef][Web of Science][Medline]

Jouvenceau A, Hedou G, Potier B, Kollen M, Dutar P, Mansuy IM (2006) Partial inhibition of PP1 alters bidirectional synaptic plasticity in the hippocampus. Eur J Neurosci 24:564–572.[CrossRef][Web of Science][Medline]

Kelly BL, Ferreira A (2006) beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 281:28079–28089.[Abstract/Free Full Text]

Klein WL (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41:345–352.[CrossRef][Web of Science][Medline]

Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556–561.[CrossRef][Web of Science][Medline]

Knobloch M, Konietzko U, Krebs DC, Nitsch RM (2007) Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging, in press.

Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453.[Abstract/Free Full Text]

Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352–357.[CrossRef][Medline]

Lin KF, Chang RC, Suen KC, So KF, Hugon J (2004) Modulation of calcium/calmodulin kinase-II provides partial neuroprotection against beta-amyloid peptide toxicity. Eur J Neurosci 19:2047–2055.[CrossRef][Web of Science][Medline]

Link W, Konietzko U, Kauselmann G, Krug M, Schwanke B, Frey U, Kuhl D (1995) Somatodendritic expression of an immediate early gene is regulated by synaptic activity. Proc Natl Acad Sci USA 92:5734–5738.[Abstract/Free Full Text]

Lisman J, Schulman H, Cline H (2002) The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci 3:175–190.[CrossRef][Web of Science][Medline]

Mansuy IM, Shenolikar S (2006) Protein serine/threonine phosphatases in neuronal plasticity and disorders of learning and memory. Trends Neurosci 29:679–686.[CrossRef][Web of Science][Medline]

Michalon A, Koshibu K, Baumgartel K, Spirig DH, Mansuy IM (2005) Inducible and neuron-specific gene expression in the adult mouse brain with the rtTA2S-M2 system. Genesis 43:205–212.[CrossRef][Web of Science][Medline]

Oddo S, LaFerla FM (2006) The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol (Paris) 99:172–179.[CrossRef][Web of Science][Medline]

Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421.[CrossRef][Web of Science][Medline]

Rowan MJ, Klyubin I, Cullen WK, Anwyl R (2003) Synaptic plasticity in animal models of early Alzheimer's disease. Philos Trans R Soc Lond B Biol Sci 358:821–828.[Abstract/Free Full Text]

Rowan MJ, Klyubin I, Wang Q, Anwyl R (2005) Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. Biochem Soc Trans 33:563–567.[CrossRef][Web of Science][Medline]

Schenk DB, Seubert P, Grundman M, Black R (2005) A beta immunotherapy: lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis 2:255–260.[CrossRef][Medline]

Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789–791.[Abstract/Free Full Text]

Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8:1051–1058.[CrossRef][Web of Science][Medline]

Strack S, Barban MA, Wadzinski BE, Colbran RJ (1997) Differential inactivation of postsynaptic density-associated and soluble Ca2+/calmodulin-dependent protein kinase II by protein phosphatases 1 and 2A. J Neurochem 68:2119–2128.[Web of Science][Medline]

Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161:1869–1879.[Abstract/Free Full Text]

Tzingounis AV, Nicoll RA (2006) Arc/Arg3.1: linking gene expression to synaptic plasticity and memory. Neuron 52:403–407.[CrossRef][Web of Science][Medline]

Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539.[CrossRef][Medline]

Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL (2002) Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133–140.[CrossRef][Web of Science][Medline]

Worley PF, Christy BA, Nakabeppu Y, Bhat RV, Cole AJ, Baraban JM (1991) Constitutive expression of zif268 in neocortex is regulated by synaptic activity. Proc Natl Acad Sci USA 88:5106–5110.[Abstract/Free Full Text]

This article has been cited by other articles:

				Y. Doi, T. Mizuno, Y. Maki, S. Jin, H. Mizoguchi, M. Ikeyama, M. Doi, M. Michikawa, H. Takeuchi, and A. Suzumura Microglia Activated with the Toll-Like Receptor 9 Ligand CpG Attenuate Oligomeric Amyloid {beta} Neurotoxicity in in Vitro and in Vivo Models of Alzheimer's Disease Am. J. Pathol., November 1, 2009; 175(5): 2121 - 2132. [Abstract] [Full Text] [PDF]

				K. Koshibu, J. Graff, M. Beullens, F. D. Heitz, D. Berchtold, H. Russig, M. Farinelli, M. Bollen, and I. M. Mansuy Protein Phosphatase 1 Regulates the Histone Code for Long-Term Memory J. Neurosci., October 14, 2009; 29(41): 13079 - 13089. [Abstract] [Full Text] [PDF]

				R. Minkeviciene, S. Rheims, M. B. Dobszay, M. Zilberter, J. Hartikainen, L. Fulop, B. Penke, Y. Zilberter, T. Harkany, A. Pitkanen, et al. Amyloid {beta}-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy J. Neurosci., March 18, 2009; 29(11): 3453 - 3462. [Abstract] [Full Text] [PDF]

				H. Taguchi, S. Planque, G. Sapparapu, S. Boivin, M. Hara, Y. Nishiyama, and S. Paul Exceptional Amyloid {beta} Peptide Hydrolyzing Activity of Nonphysiological Immunoglobulin Variable Domain Scaffolds J. Biol. Chem., December 26, 2008; 283(52): 36724 - 36733. [Abstract] [Full Text] [PDF]

				H. Taguchi, S. Planque, Y. Nishiyama, J. Symersky, S. Boivin, P. Szabo, R. P. Friedland, P. A. Ramsland, A. B. Edmundson, M. E. Weksler, et al. Autoantibody-catalyzed Hydrolysis of Amyloid {beta} Peptide J. Biol. Chem., February 22, 2008; 283(8): 4714 - 4722. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Supplemental Data Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Knobloch, M. Articles by Mansuy, I. M. Search for Related Content PubMed PubMed Citation Articles by Knobloch, M. Articles by Mansuy, I. M.

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help